clinical trial · NCT05386888
A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC
NSCLC, Stage IIIGFH018ToripalimabPaclitaxelCarboplatinCisplatinPemetrexedThoracic Radiation Therapy (TRT)GFH018
brief summary
This is a phase II trial assessing the efficacy and safety of GFH018 and Toripalimab in combination with concurrent chemoradiotherapy (cCRT) in patients with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC).
started
Sep 9, 2022
primary completion
Dec 31, 2023
completion
Dec 31, 2023
last updated
Oct 2, 2025
official title
A Phase 2 Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy for Patients With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol